{
    "id": 6994,
    "fullName": "MAPK1 A189V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAPK1 A189V lies within the protein kinase domain of the Mapk1 protein (UniProt.org). A189V has been described as a drug resistance mutation, and maintains Dusp6 and Ccnd1 expression in the absence of upstream Raf/Mek signaling in cell culture (PMID: 25320010), but has not been fully biochemically characterized and therefore, its effect on Mapk1 protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5594,
        "geneSymbol": "MAPK1",
        "terms": [
            "MAPK1",
            "ERK",
            "ERK-2",
            "ERK2",
            "ERT1",
            "MAPK2",
            "p38",
            "p40",
            "p41",
            "p41mapk",
            "p42-MAPK",
            "P42MAPK",
            "PRKM1",
            "PRKM2"
        ]
    },
    "variant": "A189V",
    "createDate": "06/03/2015",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 145563,
        "transcript": "NM_002745",
        "gDna": "chr22:g.21799055G>A",
        "cDna": "c.566C>T",
        "protein": "p.A189V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2263,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2264,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2262,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6848,
            "profileName": "MAPK1 A189V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145563,
            "transcript": "NM_002745",
            "gDna": "chr22:g.21799055G>A",
            "cDna": "c.566C>T",
            "protein": "p.A189V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145564,
            "transcript": "NM_138957",
            "gDna": "chr22:g.21799055G>A",
            "cDna": "c.566C>T",
            "protein": "p.A189V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}